1172623-95-8

Basic information

• Product Name: tert-butyl (1-[Methoxy(Methyl)aMino]-1-oxopent-4-yn-2-yl)carbaMate
• Synonyms: tert-butyl (1-[Methoxy(Methyl)aMino]-1-oxopent-4-yn-2-yl)carbaMate;tert-Butyl [1-[methoxy(methyl)amino]-1-oxo-4-pentyn-2-yl]carbamate;(1-[Methoxy(Methyl)aMino]-1-oxopent-4-yn-2-yl)carbaMate
• CAS NO: 1172623-95-8
• Molecular Formula: C₁₂H₂₀N₂O₄
• Molecular Weight: 256.2982
• EINECS: -0
• Mol File: 1172623-95-8.mol
• Article Data: 16

Chemical Properties

• Melting Point: 103-104 °C
• Appearance: /
• Density: 1.096±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 10.55±0.46(Predicted)
• CAS DataBase Reference: tert-butyl (1-[Methoxy(Methyl)aMino]-1-oxopent-4-yn-2-yl)carbaMate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl (1-[Methoxy(Methyl)aMino]-1-oxopent-4-yn-2-yl)carbaMate(1172623-95-8)
• EPA Substance Registry System: tert-butyl (1-[Methoxy(Methyl)aMino]-1-oxopent-4-yn-2-yl)carbaMate(1172623-95-8)

Safety Data

• Hazardous Substances Data: 1172623-95-8(Hazardous Substances Data)

Usage

General Description

Tert-butyl (1-[Methoxy(Methyl)aMino]-1-oxopent-4-yn-2-yl)carbamate is a specialized chemical compound, often used in scientific research and development. Comprising of various functional groups like ester, alkynes, and amines, it has a complex structural configuration. These functional groups contribute to its reactivity and potential uses. The tert-butyl portion of the molecule improves steric protection, while the methoxy(methyl)amino group can contribute to various chemical reactions. The presence of the carbamate group normally indicates potential biological activity, being commonly found in various pharmaceutical substances. As such, this chemical may be investigated for applications in chemical synthesis, pharmaceutical research, or other aspects of laboratory and industrial chemistry, although no specialized applications are evident in the literature. The exact properties like toxicity, reactivity, and environmental impact would depend on additional research.

Upstream product

• 167904-79-2 methyl (R,S)-2-(N-diphenylmethylidene)aminopent-4-ynoate 
• 100860-41-1 ethyl 2-aminopent-4-ynoate 
• 6165-75-9 propargyl benzenesulfonate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 71086-42-5 N-(diphenylmethylene)glycine ethyl ester 
• 70569-68-5 N-chloro-N-methoxy-N-methylamine 
• 171922-16-0 ethyl 2-[(diphenylmethylidene)amino]pent-4-ynoate 
• 50428-03-0 D,L-propargylglycine 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 61172-66-5 2-((tert-butoxycarbonyl)amino)pent-4-ynoic acid 
• 530-62-1 1,1'-carbonyldiimidazole 

Downstream Products

• 1172623-96-9 (±)-tert-butyl (1-(2,5-difluorophenyl)-1-oxopent-4-yn-2-yl)carbamate 
• 1172623-98-1 tert-butyl [(2R,3S)-2-(2,5-difluorophenyl)-3,4-dihydro-2H-pyran-3-yl]carbamate 
• 1172623-99-2 tert-butyl [(2R,3S)-2-(2,5-difluorophenyl)-5-hydroxytetrahydro-2H-pyran-3-yl]carbamate 
• 951127-25-6 N-[(2R,3S)-2-(2,5-difluorophenyl)tetrahydro-5-oxo-2H-pyran-3-yl]carbamic acid 1,1-dimethylethyl ester 
• 1226781-87-8 tert-butyl {(2R,3S,5R)-2-(2,5-difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-yl}carbamate 
• 1226781-44-7 Omarigliptin 

Relevant articles and documents

Evolution of a Manufacturing Route to Omarigliptin, A Long-Acting DPP-4 Inhibitor for the Treatment of Type 2 Diabetes

Development of a convergent synthesis of omarigliptin (MK-3102) suitable for commercial manufacture is described. The target molecule is assembled through a diastereoselective reductive amination of a highly functionalized pyranone with a mesylated pyrazole followed by deprotection of a Boc group. The synthesis of the pyranone relies on three Ru-catalyzed reactions: (1) a DKR reduction of a rac-α-aminoketone to set the two contiguous stereogenic centers, (2) a cycloisomerization of a bis-homopropargylic alcohol to a dihydropyran, and, finally, (3) a Ru-catalyzed oxidation of a pyranol to the desired pyranone. The regioselective synthesis of a N-Boc-1-mesyl pyrazole fragment was achieved via base-promoted mesyl group isomerization to afford 30:1 selectivity. A highlight of the endgame process development is telescoping a Boc deprotection and reductive amination followed by direct crystallization of the penultimate from the reaction mixture. This avoids handling of an unstable, mutagenic 1-mesylpyrazole BSA salt used in the earlier multikilogram deliveries and improves the overall diastereoselectivity and efficiency of the route.

AMINO PYRANOID RING DERIVATIVE AND COMPOSITION AND USE THEREOF

The present invention relates to an amino pyran ring derivative and a composition and use thereof, and in particular, to an amino pyran ring derivative represented by general formula (I) or a stereoisomer, a pharmaceutically acceptable salt or a prodrug thereof, a pharmaceutical composition comprising the derivative, and their medical use in the manufacture of a di-peptidyl peptidase IV (DPP-IV) inhibitor, in formula (I) the substituents are defined the same as those in the specification.

Amino 6-membered ring derivative and pharmaceutical applications thereof including the use for manufacturing dipeptidyl peptidase-4(IDPP-IV) inhibitor

The present invention relates to an amino 6-membered ring derivative and pharmaceutical applications thereof, which specifically relates to the amino 6-membered ring derivative represented by the general formula (I) or stereoisomers thereof, pharmaceutically acceptable salts thereof, a prodrug, a pharmaceutical composition comprising the derivative, and the pharmaceutical use for manufacturing dipeptidyl peptidase-4(IDPP-IV) inhibitor, wherein the definition of each substituent in the general formula (I) is the same as described in the specification.